Menu
Back to Journals » Clinical Audit » Volume 7
Use of continuous intrathecal baclofen in hereditary spastic paraplegia
Authors Khera J, Andrew N, Cadilhac D, Purvis T, Fahey M, Rawicki HB
Received 25 June 2015
Accepted for publication 27 October 2015
Published 15 December 2015 Volume 2015:7 Pages 19—26
DOI https://doi.org/10.2147/CA.S91140
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Marietta Stanton
Jessie Khera,1 Nadine E Andrew,1 Dominique A Cadilhac,1,2 Tara Purvis,1 Michael C Fahey,3,4 Hyam Barry Rawicki1
1Department of Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, 2Stroke Division, Florey Institute of Neurosciences and Mental Health, Heidelberg, 3Department of Paediatrics, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, 4Department of Medicine, Melbourne University, Parkville, VIC, Australia
Objective: Hereditary spastic paraplegia (HSP) is a rare progressive disorder with few treatment options. We aim to describe the effect of continuous intrathecal baclofen (ITB) pump therapy on the clinical and functional outcomes of patients with HSP.
Methods: This is a retrospective study, using medical record audit data. Adult patients with HSP who had received ITB trial or therapy and had pre- and post-ITB assessment data available were eligible for inclusion. A purposefully designed audit tool was used. Patients with a successful trial received an ITB implantable SynchroMed® II pump. Demographic, clinical, and outcome data were obtained pre- and post-pump trial and pump insertion. Functional, spasticity, and mobility measures were compared pre- and post-ITB trial and pre- and post-ITB pump insertion.
Results: Data for nine patients were available. Six were male and the median age was 55 years (Q1, Q3: 46, 55). All received an ITB trial, and those who responded favorably (n=8) had an ITB pump inserted. Following ITB therapy, improvements were demonstrated for rectus femoris (P=0.04) and gastrocnemius spasticity measures (P=0.03). All patients reported subjective improvements in function, and three of the four with pre- and post-pump assessments, demonstrated clinically meaningful improvements in mobility. Side effects were minimized with appropriate dose titrations.
Conclusion: This is the largest retrospective patient study in the field. The potential benefits of ITB in selected patients with HSP were demonstrated.
Keywords: baclofen, intrathecal baclofen, hereditary spastic paraplegia, gait analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.